Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press77610.17650/2949-5857-2025-15-1-11-17REVIEWОБЗОРЫ ЛИТЕРАТУРЫExploring the potential of bi-specific antibodies in cancer immunotherapyИзучение потенциала применения биспецифических антител при иммунотерапии ракаEskandarKirolosЭскандарКиролос
Germany

Germany

Киролос Эскандар

Germany

kiroloss.eskandar@gmail.comDiakonie Klinik Mosbach21032025151111720032025Copyright ©; 2025, Eskandar K.Copyright ©; 2025, Эскандар К.2025Eskandar K.Эскандар К.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/776

Bi-specific antibodies (BsAbs) represent a groundbreaking advancement in cancer immunotherapy, offering a novel approach to target and eliminate cancer cells by engaging two distinct antigens simultaneously. This review delves into the mechanistic foundations and clinical applications of BsAbs, highlighting their unique dual-targeting capabilities that bridge immune cells with malignant cells to enhance anti-tumor activity. We discuss the various types and design strategies of BsAbs, including their modular structures and engineering innovations that have propelled their efficacy and specificity. The review also examines preclinical and clinical trial data, showcasing the promising results and success stories in different cancer types. Despite their potential, BsAbs face challenges such as manufacturing complexities, stability issues, and toxicity concerns, which we explore alongside current solutions and regulatory considerations. By integrating the latest advancements and emerging trends, this review provides a comprehensive overview of BsAbs and their transformative role in the future of cancer therapy.

Биспецифические антитела (BsAb) – принципиально новое достижение в иммунотерапии рака. Это новый таргетный подход к удалению раковых клеток путем одновременного взаимодействия двух различных антигенов. Настоящий обзор рассматривает основы механизма действия и клинического применения BsAbs, подчеркивает их уникальные возможности воздействия на две мишени. Последнее позволяет нацеливать активность клеток иммунной системы на злокачественные клетки для усиления противоопухолевой активности. Авторы рассматривают различные типы и стратегии создания BsAb, включая их модульные структуры и инновации в области инженерии, которые повысили их эффективность и специфичность. В настоящем обзоре также представлены данные доклинических и клинических исследований, демонстрирующие многообещающие результаты и истории успеха при терапии различных типов рака. Несмотря на терапевтический потенциал, разработка BsAbs сталкивается с такими проблемами, как производственные сложности, проблемы стабильности и токсичности, которые мы рассматриваем наряду с текущими решениями, и нормативные аспекты. Объединяя последние достижения и тенденции, эта статья представляет собой исчерпывающий обзор BsAbs и их преобразующей роли в будущем терапии рака.

bi-specific antibodiescancer immunotherapydual-targetingantibody engineeringclinical applicationsбиспецифические антителаиммунотерапия ракадвойное таргетированиеинженерия антителклинические примененияMa J., Mo Y., Tang M. et al. Bispecific Antibodies: From Research to Clinical Application. Front Immunol 2021;12:626616. https://doi.org/10.3389/fimmu.2021.626616Yu S., Li A., Liu Q. et al. Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol 2017;10(1):155. https://doi.org/10.1186/s13045-017-0522-zXu G., Luo Y., Wang H. et al. Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett 2022;538:215699. https://doi.org/10.1016/j.canlet.2022.215699Wei J., Yang Y., Wang G., Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol 2022;13:1035276. https://doi.org/10.3389/fimmu.2022.1035276Moon D., Tae N., Park Y. et al. Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody. Immune Netw 2022;22(1):e4. https://doi.org/10.4110/in.2022.22.e4Blanco B., Domínguez-Alonso C., Alvarez-Vallina L. Bispecific immunomodulatory antibodies for cancer immunotherapy. Clin Canc Res 2021;27(20):5457–64. https://doi.org/10.1158/1078-0432.ccr-20-3770Marin-Acevedo J.A., Kimbrough E.O., Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncology 2021;14(1):45. https://doi.org/10.1186/s13045-021-01056-8Wu Y., Yi M., Zhu S. et al. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. https://doi.org/10.1186/s40164-021-00250-1Wang Q., Chen Y., Park J. et al. Design and Production of Bispecific Antibodies. Antibodies (Basel, Switzerland) 2019;8(3):43. https://doi.org/10.3390/antib8030043Madsen A.V., Pedersen L.E., Kristensen P., Goletz S. Design and engineering of bispecific antibodies: insights and practical considerations. Front Bioeng Biotech 2024;12:1352014. https://doi.org/10.3389/fbioe.2024.1352014Keri D., Walker M., Singh I. et al. Next generation of multispecific antibody engineering. Antib Ther 2023;7(1):37–52. https://doi.org/10.1093/abt/tbad027Franklin M.R., Platero S., Saini K.S. et al. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunotherap Cancer 2022;10(1):e003231. https://doi.org/10.1136/jitc-2021-003231Ferreira G.S., Veening-Griffioen D.H., Boon W.P.C. et al. Levelling the translational gap for animal to human efficacy data. Animals: an open access journal from MDPI 2020;10(7):1199. https://doi.org/10.3390/ani10071199Costes L.M., Meresse B., Cerf-Bensussan N., Samsom J.N. The role of animal models in unravelling therapeutic targets in coeliac disease. Best Pract Res Clin Gastroenterol 2015;29(3): 437–50. https://doi.org/10.1016/j.bpg.2015.04.007Tubau-Juni N., Hontecillas R., Ehrich M. et al. Preclinical Studies: Efficacy and Safety. In: Accelerated Path to Cures. 2018. P. 25–40. https://doi.org/10.1007/978-3-319-73238-1_3Falchi L., Jardin F., Haioun C. et al. Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: preliminary safety and efficacy results. 2023, December 11. https://ash.confex.com/ash/2023/webprogram/Paper173953.htmlEsfandiari A., Cassidy S., Webster R.M. Bispecific antibodies in oncology. Nat Rev Drug Discov 2022;21(6):411–2. https://doi.org/10.1038/d41573-022-00040-2MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies as. Memorial Sloan Kettering Cancer Center. 2023, December 11. https://www.mskcc.org/clinical-updates/msk-ash2023-insights-promising-results-for-bispecific-antibodies-as-firstline-therapies-for-patients-with-follicular-and-cell-lymphomaWu Y., Yi M., Zhu S. et al. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10(1):56. https://doi.org/10.1186/s40164-021-00250-1Challenges of Manufacturing the Expanding Range of Bi/ Multispecific Modalities. https://www.pharmasalmanac.com/articles/challenges-of-manufacturing-the-expanding-range-ofbimultispecific-modalitiesSun Y., Yu X., Wang X. et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B 2023;13(9):3583–97. https://doi.org/10.1016/j.apsb.2023.05.023Ott P.A., Hodi F.S., Kaufman H.L. et al. Combination immunotherapy: a road map. J Immunotherap Cancer 2017;5:16. https://doi.org/10.1186/s40425-017-0218-5You G., Won J., Lee Y. et al. Bispecific Antibodies: A smart arsenal for cancer immunotherapies. Vaccines 2021;9(7):724. https://doi.org/10.3390/vaccines9070724Zhu S., Zhang T., Zheng L. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14(1):156. https://doi.org/10.1186/s13045-021-01164-5Bispecific Antibodies (n.d.). https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodiesAntibody therapeutics approved or in regulatory review in the EU or US – The Antibody Society. 2024, July 29. https://www.antibodysociety.org/resources/approved-antibodies/Huang X., Zhu M., Chen R. et al. Innovative drugs promote precision cancer therapy. Clinical Cancer Bulletin 2023;2(1). https://doi.org/10.1007/s44272-023-00002-8Powering the future of precision oncology medicine with big data. (2023). In: www.carislifesciences.com.